REG - C4X Discovery - Director/PDMR Share Purchases

C4X Discovery HoldingsAnnouncement

09/04/2024 11:00

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20240409:nRSI8719Ja&default-theme=true

RNS Number : 8719J  C4X Discovery Holdings PLC  09 April 2024

C4X Discovery Holdings plc

("C4XD", "C4X Discovery" or the "Company")

 

Director/PDMR Share Purchases

9 April 2024 - C4X Discovery Holdings plc (AIM: C4XD), a pioneering Drug
Discovery company, was informed on 8 April 2024 that Clive Dix, Executive
Chairman of the Company, purchased 485,320 ordinary shares of 0.01 pence each
("Ordinary Shares") in the Company at a price of 10.3 pence per share.

Following this purchase of shares, Clive Dix has a beneficial interest in
2,071,809 Ordinary Shares, representing approximately 0.82 per cent. of the
Company's issued share capital.

Further information on the purchases is contained in the disclosure tables
below.

 

Contacts

 C4X Discovery Holdings
 Mo Noonan, Communications                                 +44 (0)787 6444977

 Panmure Gordon (UK) Limited (NOMAD and Broker)
 Freddy Crossley, Emma Earl (Corporate Finance)            +44 (0)20 7886 2500
 Rupert Dearden (Corporate Broking)

 C4X Discovery Media - Consilium Strategic Communications
 Mary-Jane Elliott, Chris Gardner                          +44 (0)203 709 5700

 

 

NOTIFICATION AND PUBLIC DISCLOSURE OF TRANSACTIONS BY PERSONS DISCHARGING
MANAGERIAL RESPONSIBILITIES AND PERSONS CLOSELY ASSOCIATED WITH THEM:

 1    Details of the person discharging managerial responsibilities / person closely
      associated
 a)   Name                                                         Clive Dix
 2    Reason for the notification
 a)   Position/status                                              Executive Chairman
 b)   Initial notification /Amendment                              Initial notification

 3    Details of the issuer, emission allowance market participant, auction

    platform, auctioneer or auction monitor

 a)   Name                                                         C4X Discovery Holdings plc
 b)   LEI                                                          213800UHNL82E323O870
 4    Details of the transaction(s): section to be repeated for (i) each type of

    instrument; (ii) each type of transaction; (iii) each date; and (iv) each
      place where transactions have been conducted
 a)   Description of the financial instrument, type of instrument  Ordinary shares of £0.01 each

      Identification code

                                                                   GB00BQQ2RV18
 b)   Nature of the transaction                                    Purchase of Shares
 c)   Price(s) and volume(s)                                         Price(s)    Volume(s)
                                                                   10.3 pence    485,320

 
 d)   Aggregated information                                       n/a

      - Aggregated volume

      - Price
 e)   Date of the transaction                                      8 April 2024
 f)   Place of the transaction                                     London Stock Exchange

 

d)

Aggregated information

- Aggregated volume

- Price

n/a

e)

Date of the transaction

8 April 2024

f)

Place of the transaction

London Stock Exchange

 

 

Notes to Editors:

About C4X Discovery

C4X Discovery (C4XD) is a pioneering Drug Discovery company, combining
scientific expertise with cutting-edge technologies to efficiently deliver
world‑leading medicines. We have a highly valuable and differentiated
approach to Drug Discovery through our enhanced molecular design and patient
stratification capabilities, generating small molecule drug candidates across
multiple disease indications focused on immuno-inflammation. We are advancing
our internal portfolio which ranges from early-stage target opportunities to
late-stage Drug Discovery programmes and we have two commercially partnered
programmes with Sanofi and AstraZeneca, and one clinical stage candidate which
has been acquired by Indivior.

 

For more information visit us at www.c4xdiscovery.com
(http://www.c4xdiscovery.com) or follow us on twitter @C4XDiscovery.

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  DSHQKCBPCBKKOQK